Modulation of programmed cell death pathways by the hepatitis C virus by Aweya, Jude Juventus & Tan, Yee-Joo
[Frontiers in Bioscience xx, xxxx-xxxx, xxxx]   
 1




Jude Juventus Aweya1,2 and Yee-Joo Tan1,2,* 
 
1Department of Microbiology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore. 







TABLE OF CONTENTS 
 
1. Introduction 
2. Contribution of structural proteins to apoptosis regulation 
2.1. Core 
2.1.1. Effects of core on extrinsic apoptotic pathways 
2.1.2. Effects of core on intrinsic apoptotic pathways 
2.1.3. Effects of core on other cellular pathways that contribute to apoptosis regulation 
2.1.4. Effects of alternate reading frame proteins on apoptosis 
2.2. E1 and E2 
3. Contribution of non-structural proteins to apoptosis regulation 
3.1. p7  
3.2. NS2 
3.3. NS3  
3.4. NS4A  
3.5. NS5A  
3.6. NS5B  
4. Apoptosis during infection by recombinant HCVcc 
5. Involvement of other cell death pathways 










Hepatitis C virus (HCV), a positive-stranded RNA virus of the family Flaviviridae, is one of the major causes of liver 
diseases like cirrhosis, steatosis, and hepatocellular carcinoma.  It currently infects an estimated 3% of people worldwide and 
poses an important medical problem in both developed and developing countries.  The virus exhibits a very high degree of 
genetic diversity that is classified by phylogenetic analysis into six genotypes, each of which contains numerous subtypes (1).  
The current therapy with pegylated interferon plus ribavirin is not optimal because a significant proportion of patients failed to 
achieve a sustained virological response (see recent reviews (2-4).  The failure rate is almost 50 % for patients with genotype 1 
HCV and approximately 20% for those with genotype 2 or 3 HCV.  In addition, many patients can not complete the treatment 
due to the substantial side effects. 
The HCV genome encodes a unique open reading frame that is translated into a precursor polyprotein of about 3000 
residues.  The polyprotein is cleaved co- and post-translationally by viral and cellular proteases to yield at least three structural 
(core, E1 and E2) and seven non-structural (p7, NS2, NS3, NS4A, NS4B, NS5A and NS5B) viral proteins (Figure 1).  These 
proteins have important roles at different steps of the virus life cycle and are involved in viral-viral as well as viral-host 
interactions (see a recent review (5)).   
Many of these molecular aspects of HCV replication have been studied using the replicon systems where the viral RNA 
self-amplifies in human hepatoma cells (see the recent review (6)).  More recently, an infectious clone of HCV has recently been 
developed to produce HCV robustly in cell culture (known as the HCVcc system (7)).  This is based on the JFH-1 strain, which is 
a genotype 2a strain from a Japanese patient with fulminant hepatitis.  This strain of HCV has been shown to produce moderate 
titers of infectious virus in cell culture systems without adaptation.  The availability of the HCVcc system has allowed detailed 
investigation into different steps in the virus life cycle including entry, replication, assembly and release. 
In the fight for survival between virus and host, cell death regulation is an important determinant and many viruses 
encode for proteins that can interfere with the cellular cell-death signaling, skewing it to their advantage (8-10).  The most well-
studied programmed cell death pathway is apoptosis.  Induction of apoptosis in infected cells can contribute directly to the viral 
pathogenesis and/or dissemination, while inhibition of apoptosis can prevent premature death of the infected cells, allowing the 
virus to replicate to a high titer or allowing the establishment of a persistent infection.  In order to modulate apoptosis, viral 
proteins can interact with various host proteins that regulate the extrinsic and intrinsic apoptotic pathways.  The extrinsic pathway 
is also known as the receptor pathway and is activated through binding of ligands to cell membrane receptors, such as Fas, tumor 
necrosis factor (TNF) and tumor-necrosis-related apoptosis-inducing ligand (TRAIL) receptors (11).  On the other hand, the 
intrinsic pathway is dependent on mitochondrial resident proteins which control the release of a number of factors, like 
cytochrome c, from the mitochondrial intermembrane space (12).  These factors then promote and amplify the apoptotic cascade 
from the formation and activation of the apoptosomes to the final destruction of the cell.   
Although HCV is a non-lytic virus, it is known to modulate apoptosis in the host cell through various mechanisms.  
Indeed, both proapoptotic and prosurvival properties have been attributed to different HCV proteins, most commonly, through 
studies using ectopic expression of individual proteins in cell culture systems.  Studies using the replicon and HCVcc system 
have also yield important insights into the modulation of programmed cell death by HCV replication.  In this review, we will 
summarize current knowledge on the modulation of apoptosis and other programmed cell death pathways by the HCV in these 




2. CONTRIBUTION OF STRUCTURAL PROTEINS TO APOPTOSIS REGULATION 
 
2.1. Core 
The core protein is encoded by the N-terminal portion of the HCV precursor polyprotein and cleaved from the 
polyprotein by cellular signal peptidase to give the immature form of the core protein (residues 1 to 191). This then is further 
cleaved by membrane-associated signal peptide peptidase to give the mature core protein, whose C terminus is not precisely 
known but lies between residues 170 and 179 (see reviews (13-15)).  Besides its role in the encapsidation of viral RNA, core has 
been found to interfere with many cellular pathways, including cell signaling, transcriptional activation, lipid metabolism, 
carcinogenesis, and apoptosis (see reviews (13-15)).   
Depending on the death stimuli and types of cells used, core has been reported to inhibit as well as promote apoptosis.  
As both the immature and mature forms of core have been used in these studies, some differences in the activity of core observed 
may also be related to the form of core expressed.  A summary of the different apoptotic pathways that are affected by core is 
provided below.  Many of these studies were performed by ectopic expression of core alone and should be re-examined in the 
context of productive HCV replication where the other HCV proteins are also expressed.  In particular, the HCVcc system can be 
used to determine if the level of core in the infected cells is sufficient to modulate the specific apoptotic pathways.  Overall, it 
appears that multiple domains present in the core protein contribute to the modulation of apoptosis via diverse pathways. 
Therefore, the net apoptotic effect of the core protein may be dependent on the relative strength of its prosurvival and 
proapoptotic properties.  However, the relative contribution of these various factors to apoptosis induction during HCV infection 
remains to be determined. 
 
 2.1.1. Effects of core on extrinsic apoptotic pathways  
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Core has been shown to interact directly with various components of the extrinsic apoptotic pathways, resulting in 
sensitization to Fas- and TNF- mediated apoptosis.  Core was found to act as a positive regulator of Fas-mediated apoptosis in 
several cell lines (16-18).  Interestingly, the C-terminal domain (residues 153 to 192) facilitates Fas oligomerization and is 
required for apoptosis induction in Jurkat cells in a Fas ligand-independent manner (18).  Core has also been shown to bind the 
death domain (DD) of TNF receptor-1 as well as one of its signaling molecules Fas-associated death domain protein (FADD) (19, 
20).  Consequently, the core-expressing cells are sensitized to TNF-mediated apoptosis.  As for TRAIL (also called Apo2L), 
which is a novel TNF superfamily member with strong homology to Fas ligand, there is one study that showed that core enhances 
TRAIL-mediated apoptosis via a mitochondrial-dependent signaling pathway (21).  
 On the other hand, core seems to inhibit Fas- or TNF- mediated apoptosis via several indirect pathways.  These include 
the activation of nuclear factor κB (NF-κB) and the upregulation of inhibitor of caspase-activated DNase (22, 23).  Core has also 
been shown to inhibit caspase-8 activation by sustaining the expression of cellular FLICE (FADD-like interleukin-1β-converting 
enzyme)-like inhibitory protein (c-FLIP) (24).   
 
2.1.2. Effects of core on intrinsic apoptotic pathways 
Core is localized to various cellular compartments including the surface of lipid droplets, nucleus, endoplasmic 
reticulum (ER) and mitochondria (see recent review (25)).  As mitochondria are key sites for the regulation of apoptosis induced 
by intrinsic stimuli, it is not surprising that core has a direct functional effect on mitochondria.  In transgenic mice and various 
cell lines, the expression of core causes an increase in mitochondrial reactive oxygen species (ROS) production and lead to 
apoptosis induction (26-32).   The precise mode of action that leads to increased ROS production is not clearly defined but the N-
terminal domain (residues 1 to 75)  of core has been shown to interact with Hsp60, a stress response molecular chaperon that is 
primarily compartmentalized in mitochondria matrix (32).  The interaction between core and Hsp60 was found to be important 
for the increased ROS production and the sensitization of the cells to apoptosis while the overexpression of Hsp60 rescued the 
core-expressing cells from apoptosis (32).  It was also reported that core increases the mitochondrial Ca2+ uptake and causes 
oxidation of the glutathione pool (26).  Subsequently, there is a reduction in the activity of the electron transport complex I and 
an increase in ROS production (26).  Another study showed that core stimulates the mitochondrial Ca2+ uniporter activity, 
resulting in increased mitochondrial Ca2+ uptake in response to ER Ca2+ release (27).  Interestingly, core also triggers apoptosis 
by inducing ER stress and causing ER Ca2+ depletion (33).  Subsequently, mitochondrial dysfunction occurs due to the changes 
in Ca2+ homeostasis.  Thus, core-induced apoptosis may be due to a combination of actions at both the ER and mitochondria.    
The family of Bcl-2 proteins plays important roles in regulating the mitochondrial apoptotic pathway (34, 35).  There 
are at least 12 different members in the Bcl-2 family and they may be classified broadly into three classes: prosurvival members 
containing multiple Bcl-2 homology (BH) domains, proapoptotic members containing multiple BH domains, and proapoptotic 
members containing the BH3 domain only.  Members of the Bcl-2 family are also involved in viral infections as numerous 
viruses have been shown to encode homologs of prosurvival Bcl-2 proteins, and these viral proteins act to inhibit apoptosis in 
infected cells and prevent the premature death of these cells (see reviews (36, 37)).  Recently, a Bcl-2 homology domain 3 (BH3) 
in the core protein of the HCV-S1 strain (genotype 1b) was identified and shown to be essential for its proapoptotic property (38).  
Core appears to be a bona fide BH3-only protein having properties similar to those of Noxa, a BH3-only member of the Bcl-2 
family that binds preferentially to Mcl-1, a prosurvival member of the Bcl-2 family.  Interestingly, the genotype 1b core protein is 
more effective than the genotype 2a core protein (of the JFH-1 strain) in inducing apoptosis due to a single-amino-acid 
difference.   
However, two independent studies reported that core can exert prosurvival effects at the mitochondria (29, 39).  Using 
transiently transfected and magnetically collected core-producing HepG2 and Huh7 with core expression under control of the 
Tet-Off promoter, these studies reported that the mRNA and protein levels of the pro-survival Bcl-XL were increased by core.  
Subsequently, these cells are more resistant to apoptosis induced by deoxycholic acid, TNF-alpha (with actinomycin D) or Fas 
stimulation.   
 
2.1.3. Effects of core on other cellular pathways that contribute to apoptosis regulation 
The effects of core on several cellular pathways also lead to the induction of apoptosis indirectly.  For example, core 
interacts with 14-3-3, resulting in the release of Bax from the Bax/14-3-3  complex in the cytoplasm and activation of apoptosis 
(40).  One important consideration may be the cellular localization of different forms of core as this will impact on core’s 
interaction with host-factors.  Indeed, it was reported that the effect of core on p53 and p21 activities is dependent on its 
subcellular location (41, 42).  As such, core has been shown to promote as well as inhibit p53-mediated apoptosis (41, 43, 44).  
The proapoptotic effect of core was also reported to be enhanced by nuclear localization and found to be correlated to protein 
kinase R (PKR) activation (45). 
 
2.1.4. Effects of alternate reading frame proteins on apoptosis 
HCV has an alternate reading frame (ARF) that overlaps the core protein gene and several ARF proteins are expressed 
(see recent reviews (46, 47)).  There are limited studies on these proteins but one study reported that one of these ARF proteins, 
termed as the F protein, can inhibit TNF-mediated apoptosis by activating the NF-κB pathway (48). 
 
2.2. E1 and E2 
HCV encodes two glycoproteins, E1 and E2, which interact to form complexes on the surface of the virion and mediate 
viral attachment and entry through interaction with cellular receptors (see recent review (49)).  Beside this role, E1 and E2 are 
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also involved in modulating cellular functions when they are expressed intracellularly.  For example, the overexpression of E1 
induced apoptosis in HepG2 cells and this could be partially blocked by caspase inhibitors (50).  The induction of apoptosis was 
also found to be dependent on the transmembrane domain at the C terminal of E1 and may be due to the alternation of ER 
membranes by E1. 
 The effects of E2 on apoptosis regulation are more complicated as both proapoptotic and prosurvival effects have been 
observed.  When E2 was transiently expressed in various cell-lines, including Huh7, apoptosis was observed (51, 52).  
Expression of E2 caused cytochrome c release and cleavage of Bid, suggesting that a mitochondrial pathway is involved (52).  
However, the binding of recombinant E2 to the surface of Huh7.5 or Daudi cells was also sufficient to cause a decrease in cell 
viability (53, 54).  This suggests that E2 can also induce apoptosis presumably via an “innocent bystander” mechanism that 
resulted from the binding of E2 to CD81 on the cell surfaces.   In contrast, the binding of E2 to primary thyroid cells did not 
induce apoptosis but caused secretion of IL8 (54).   
Interestingly, Munshi and co-workers showed that E2 can act cooperatively with the envelope protein of the human 
immunodeficiency virus type 1 (HIV-1), gp120, to induce apoptosis in HepG2 cells (55).  Similar to the studies described above, 
this involves an “innocent bystander” mechanism that resulted from the cell surface binding of these proteins and is independent 
of viral replication (55).  Further studies revealed that the apoptosis induction is caused by activation of the signal transducer and 
activator of transcription factor 1 (STAT1) which leads to increased Fas ligand expression and translocation of Bid to the 
mitochondria (56, 57).  As the potential cross-talk between HIV-1 and HCV may affect the treatment of HIV-1 and HCV co-
infected patients (see recent review (58)), it is important to examine the clinical significance of these findings in future studies.  
However, prosurvival activity was observed in stable cell lines expressing E2 (59).  Replicon-containing Huh7 cells 
that stably express core, E1 and E2 showed resistance to TRAIL-induced apoptosis when compared to the parental Huh7.  As this 
effect was not observed in replicon-containing Huh7 cells that stably express core and E1, it seems that E2 is responsible for the 
prosurvival effect and this is confirmed by experiments performed using Huh7 cells stably expressing E2 only.  Furthermore, the 
level of several survival genes related to NF-κB activation were found to be up-regulated in the E2-expressing cells (60).  One of 
them is the molecular chaperone glucose-regulated protein (GRP) 94 and RNA interference experiments showed that GRP94 is 
essential for the resistant to TRAIL-induced apoptosis in both E2-expressing cells or Huh-7 infected with JFH-1 recombinant 
HCVcc (60).  Taken together, the HCV E2 modulates apoptosis via several pathways.  The difference in the property of E2 




3. CONTRIBUTION OF NON-STRUCTURAL PROTEINS TO APOPTOSIS REGULATION 
 
Besides the structural proteins, HCV also encodes 6 non-structural proteins and a small p7 protein, which has not been 
formally designated as structural or non-structural.  For simplicity, p7 is classified as non-structural in this review.  With the 
exception of NS4B, all of these proteins have been shown to have either proapoptotic or prosurvival or both activities (Figure 1).  
This is summarized in this section. 
 
3.1. p7  
The p7 protein is a small highly hydrophobic protein located at the junction between the structural and nonstructural 
proteins (5). P7 has ion channel activity and is thus classified in the family of viral ion channel proteins known as viroporins (61, 
62).  Recently, Madan et al demonstrated that HCV p7 protein induces caspase-dependent apoptosis in baby hamster kidney cells 
(63).  However, the level of apoptosis induced by p7 seems to be much lower than that induced by other viroporins (63).   
 
3.2. NS2  
NS2, one of the two viral proteases required for the post-translational cleavage of the nonstructural proteins, is a 
hydrophobic transmembrane protein anchored to the ER (5).  Erdtmann et al demonstrated that NS2 was able to interact with and 
inhibit apoptosis induced by the liver-specific pro-apoptotic CIDE-B protein. The prosurvival activity of NS2 is believed to be 
related to its ability to interfere with the cell-death pathway by binding to the CIDE-B cell death domain (64).   
 
3.3. NS3  
HCV NS3 is a multifunctional protein believed to be involved in several essential processes in the virus lifecycle, such 
as protease, nucleotide triphosphatase and RNA helicase activity (5). Apart from these enzymatic activities, NS3 has been 
reported to have both proapoptotic and prosurvival activities.  For instance, in actinomycin D treated cells, NS3 was shown to 
suppress apoptosis by forming a complex with the tumor suppressor p53, and thus decreasing the amount of p53 through a 
decrease in transcription and/or translation of p53 or through the degradation of p53 (65, 66).  
On the other hand, Siavoshian et al, demonstrated that NS3 was proapoptotic in mature dendritic cells and that the 
proapoptotic effect was due to its ability to down-regulate the expression of p21waf1/cip1 (67).  Similarly, when expressed in human 
and simian cells by transient transfections, NS3 and its precursor NS2/3 have been shown to induce caspase-8-mediated apoptosis 
(68).  Site-directed mutagenesis showed that the proapoptotic activity of NS3 is independent of its protease and helicase activities 
(68).  In phagocytes, the expression of NS3 led to the release of ROS from phagocytes by activating the enzyme, reduced 
nicotinamide adenine dinucleotide phosphate (NADPH) oxidase (69). The activated phagocytes subsequently induced apoptosis 
in both T cells and NK cells (69). 
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The discrepancies in reports of the apoptotic ability of NS3 may be partly due to the different cell lines used in the 
studies.  For instance, it was observed that the induction of apoptosis is higher in Vero and HepG2 cells than in Huh-7 cells (68). 
 
3.4. NS4A  
HCV NS4A is a small protein which acts as a cofactor for NS3in its protease activity (5). NS4A is reported to be 
proapoptotic because it has a mitochondrial-damaging effect (70). For instance, using Huh-7 cells, it has been shown that NS4A 
is able to decrease the transmembrane potential of the mitochondrial resulting in the release of cytochrome C and the activation 
of caspase-3 followed by cell death (70).  Just like p7, NS4A has been shown to have ion channel activities and is classified as a 
viroporin (63).  Among the various viroporins tested for proapoptotic activities, NS4A caused the most rapid induction of 
caspase-3 activiation and triggered the release of cytochrome c efficiently (63). 
 In two separate studies, NS3 and NS4A were expressed as a complex but opposite effects on apoptosis were observed.  
The NS3/4A complex was reported to inhibit apoptosis induced by the mitochondrial antiviral signaling adaptor protein (MAVS), 
also known as IPS-1, VISA or Cardif, by cleaving MAVS at its transmembrane domain, resulting in its dissociation from the 
mitochondria and thus destroying its proapoptotic functions (71).  In contrast, Nomura-Takigawa et al. observed that the NS3/4A 
complex sensitized cells to actinomycin D-induced mitochondria-mediated apoptosis (70). 
 
3.5. NS5A  
The HCV NS5A protein is a phosphoprotein which interacts with several host proteins and signaling pathways (72, 73).  
With regards to apoptosis, it has been shown to inhibit both extrinsic and intrinsic apoptotic stimuli.  For example, NS5A has 
been shown to inhibit TNF- mediated apoptosis (74-76).  The only exception was observed in mature dendritic cells where the 
overexpression of NS5A induced apoptosis (67). 
The prosurvival activities of NS5A appear to result from its ability to interact with various host proteins.  For example, 
NS5A is a potential viral Bcl-2 homologue and is able to bind Bax via its BH2 domain, thus inhibiting apoptosis by sequestering 
Bax in the nucleus (77).  The BH1 domain in NS5A was also shown to interact with the FK506-binding protein 38 (FKBP38) 
and the prosurvival activity of NS5A was reduced when the expression of endogenous FKBP38 was suppressed by RNA 
interference (78).  On the other hand, a Src homology 3 domain in NS5A was found to be responsible for its interaction with 
Bin-1 and inhibition of Bin-induced apoptosis (79).  Other studies linked the prosurvival activity of NS5A to its ability to bind 
p53, PKR protein kinase, Grb 2 or p85 phosphatidylinositol 3-kinase (80-83).  It also has the ability to activate a calpain cysteine 
protease, leading to the degradation of Bid, and inhibit the oxidative-stress induced p38 MAPK phosphorylation of Kv2.1 (84, 
85). Both of these resulted in dampening of the apoptotic signaling. 
 
3.6. NS5B  
HCV NS5B is the viral RNA-dependent RNA polymerase (5).  Thus far, it has only been shown to induce apoptosis in 




4. APOPTOSIS DURING INFECTION BY RECOMBINANT HCVcc  
 
With the production of recombinant HCVcc, it becomes clear that HCV infection of hepatoma cells leads to cell death 
with numerous hallmarks of apoptosis like exposure of phosphatidylserine on the outer surface of the plasma membrane, 
activation of caspase 3, nuclear condensation and DNA fragmentation (86-89).  The mitochondrial pathway was clearly affected 
by HCV infection as it triggers Bax activation, leads to disruption of mitochondrial transmembrane potential and release of 
cytochrome c (89).  In addition, there is oxidative stress due to the enhanced level of mitochondrial ROS (89-92).  This could be 
related to the ability of core to increase mitochondrial ROS (see above). 
However, it is unclear if ER stress is also involved in HCVcc-induced apoptosis.  ER stress markers, like GRP78, was 
found to be upregulated in one study (88) but another (89).  The difference may be due to the use of different strain of virus (JFH-
1 or intragenotypic chimeric J6/JFH-1) or multiplicity of infection.  However, HCV infection has also been shown to induce ER 
stress and sensitize infected cells to apoptosis in the SCID/Alb-uPA mice (93).  Studies using the subgenomic replicon systems 
also suggested that HCV replication disrupts normal ER functions and induces ER stress (see review (94)).  Thus, it appears that 
ER stress can contribute to HCV-induced apoptosis but the induction of mitochondrial ROS and HCV-induced apoptosis can also 
occur independently of ER stress. 
Recently, a Bcl-2 homology domain 3 (BH3) in the core protein of the HCV-S1 strain (genotype 1b) was identified and 
found to be essential for its proapoptotic property (38).  Interestingly, the genotype 1b core protein is more effective than the 
genotype 2a core protein (of the JFH-1 strain) in inducing apoptosis due to a single-amino-acid difference.  Consistently, 
substitution of this residue in the J6/JFH-1 infectious clone (genotype 2a) with the corresponding amino acid in the genotype 1b 
core protein produced a mutant virus, J6/JFH-1(V119L), which induced significantly higher levels of apoptosis in the infected 
cells than the parental J6/JFH-1 virus.  Interestingly, more progeny virus is released from cells infected with the J6/JFH-
1(V119L) virus than by those infected with the parental J6/JFH-1, while there is no difference in the efficiency of infection or 
amount of HCV replication inside the cells. The enhanced releases of virus from infected cells that are undergoing apoptosis have 
been reported for other viruses, like the infectious bursal disease virus, adenovirus, and Aleutian mink disease parvovirus (95-
97), indicating that apoptosis can be advantageous for viral spreading at the late stages of infection.  Mateu and co-workers also 
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reported that a correlation between the level of infectious particles produced and the level of cell-death in Huh7 transfected with 
intragenotypic JFH1 based viral RNA (87). 
In another study, it was found that HCVcc infection sensitizes Huh7.5 cells and primary human hepatocytes (PHH) to 
TRAIL-induced apoptosis (98).  Furthermore, this enhancement was shown to be mediated by the HCV nonstructural proteins 
and is caspase-9 dependent.  A low level of apoptosis was also observed in the HCV RNA transfected Huh7.5 cells but the level 
of apoptosis increased dramatically upon TRAIL treatment.  This indicates that there is a synergistic activation of both the 
extrinsic and intrinsic apoptotic pathways.  In another hepatoma cell-line, LH86, massive apoptosis was also observed upon HCV 
infection (86).  Interestingly, HCV infection of LH86 cells caused a significantly higher level of increase in TRAIL mRNA levels 
when compared to infected Huh7.5 cells and this seems to be correlated to the higher level of apoptosis observed in LH86 cells 
(86).  Furthermore, it was demonstrated that IRF-3 is responsible for both IFN beta production and TRAIL induction in infected 
LH86 cells (86). 
 Most of the current HCVcc studies are based on the genotype 2a JFH-1 genome or intragenotypic JFH-based genomes.  
On the other hand, most of the ectopic expression studies (described above) were performed using viral proteins from genotype 
1a or 1b HCV strains.  It is expected that future studies will reveal more about apoptosis regulation during infection especially 




5. INVOLVEMENT OF OTHER CELL-DEATH PATHWAYS  
 
Apoptosis is the most well-characterized cell death pathway during viral infection.  However, emerging evidence 
suggests that non-apoptotic cell death pathways are also highly regulated cellular suicide processes and contribute to pathological 
injury (99-101). 
Autophagy is a highly regulated cellular process, by which cytoplasmic materials are enclosed within double (or 
multiple) membrane vesicles and shuttled to lysosmes for their degradation, and the participation of host autophagic machinery in 
viral infection is increasingly being recognized (102, 103).  Several independent studies have shown that HCV replication 
induces an autophagic response in hepatocytes (104-108).  RNA interference experiments revealed that the autophagy machinery 
is important for HCV replication (104, 106, 107).  However, the autophagy machinery may affect more than one step in the virus 
life cycle.  Dreux and co-workers showed that autophagy proteins are need to initiate HCV RNA translation/replication of the 
incoming viral RNA in the HCVcc system but they are not essential in maintaining it once these processes are established in the 
replicon system (107).  On the other hand, the study by Tanida and co-workers suggests that autophagy proteins are involved in 
the production of infectious HCV particles (106).   
Another major form of cell-death is necrosis which was initially thought to be an uncontrolled form of cell death, but 
recent studies have revealed that programmed cell necrosis, also known as necroptosis, is a genetically controlled pathway (99, 
100,109).  There is a lack of systematic studies on the role of necroptosis in HCV infection.  A recent study showed that the core 
protein can induce caspase-independent cell death (110).  However, typical apoptosis-associated morphological features were 
observed and it is not yet determine if autophagic cell-death or necroptosis is involved.  Unlike apoptosis, the contributions of the 
different HCV proteins to other forms of cell-death have not been extensively studied and it is likely that future studies will 




6. FUTURE STUDIES 
Extensive studies have been performed to understand the mechanisms by which HCV proteins regulate apoptosis.  In 
addition, recent studies have characterized the cell death pathways that are activated in HCV infected cells by using the genotype 
2a JFH-1 (or intragenotypic chimeric of JFH-1) HCVcc system.  Further studies are need to delineate the contributions of the 
different HCV proteins to the regulation of apoptosis, as well as other cell death pathways, and understand the role of viral 
apoptosis at different stages of the HCV life-cycle.  Advances in the development of a small animal HCV infection model will be 
necessary to provide additional insights into the contributions of cell death to HCV replication and pathogenesis.  Potential 
genotype differences will also be addressed when infectious clones of different genotypes are successfully generated.  Research 
on the interaction between HCV and cell death pathways will eventually lead to a better understanding of intricate interplay 
between HCV and its human host and may contribute to the development of antiviral therapeutics and design of efficient 
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Figure legends  
Figure 1. Schematic diagram showing the HCV proteins and their involvement in apoptosis regulation.  Upward 
arrows indicate proapoptotic activities while downward arrows indicate prosurvival activities.  Alternate reading 
frame proteins are not indicated. UTR: untranslated region, IRES: internal ribosome entry site. 
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